4.6 Article

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

期刊

BMC CANCER
卷 18, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s12885-018-4238-4

关键词

Pancreatic Cancer; PDAC; Organoid; Organotypic culture; Microenvironment; Tumor stroma; Tumor immunology; TILs; CAFs

类别

资金

  1. Batterman Foundation
  2. Ronald Burkland Eich Pancreatic Cancer Research Fund, Department of Surgery, Medical College of Wisconsin
  3. MCW Cancer Center
  4. American Cancer Society [14-247-29-IRG]
  5. We Care Fund for Innovation and Discovery from the Department of Surgery, Medical College of Wisconsin

向作者/读者索取更多资源

Background: Patient-derived tumor models are the new standard for pre-clinical drug testing and biomarker discovery. However, the emerging technology of primary pancreatic cancer organoids has not yet been broadly implemented in research, and complex organotypic models using organoids in co-culture with stromal and immune cellular components of the tumor have yet to be established. In this study, our objective was to develop and characterize pancreatic cancer organoids and multi-cell type organotypic co-culture models to demonstrate their applicability to the study of pancreatic cancer. Methods: We employed organoid culture methods and flow cytometric, cytologic, immunofluorescent and immunohistochemical methods to develop and characterize patient-derived pancreatic cancer organoids and multi-cell type organotypic co-culture models of the tumor microenvironment. Results: We describe the culture and characterization of human pancreatic cancer organoids from resection, ascites and rapid autopsy sources and the derivation of adherent tumor cell monocultures and tumor-associated fibroblasts from these sources. Primary human organoids displayed tumor-like cellular morphology, tissue architecture and polarity in contrast to cell line spheroids, which formed homogenous, non-lumen forming spheres. Importantly, we demonstrate the construction of complex organotypic models of tumor, stromal and immune components of the tumor microenvironment. Activation of myofibroblast-like cancer associated fibroblasts and tumor-dependent lymphocyte infiltration were observed in these models. Conclusions: These studies provide the first report of novel and disease-relevant 3D in-vitro models representing pancreatic tumor, stromal and immune components using primary organoid co-cultures representative of the tumor-microenvironment. These models promise to facilitate the study of tumor-stroma and tumor-immune interaction and may be valuable for the assessment of immunotherapeutics such as checkpoint inhibitors in the context of T-cell infiltration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression

Michael A. James, William L. Seibel, Elena Kupert, Xiao X. Hu, Vishwakanth Y. Potharla, Marshall W. Anderson

ANTI-CANCER DRUGS (2015)

Article Biochemistry & Molecular Biology

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

Yongik Lee, Yian Wang, Michael James, Joseph H. Jeong, Ming You

MOLECULAR CARCINOGENESIS (2016)

Article Biochemistry & Molecular Biology

Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus

Rachel Lieberman, Donghai Xiong, Michael James, Younghun Han, Christopher I. Amos, Liang Wang, Ming You

MOLECULAR CARCINOGENESIS (2016)

Article Oncology

Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling

Laszlo G. Puskas, Imola Man, Gabor Szebeni, Laszlo Tiszlavicz, Susan Tsai, Michael A. James

MOLECULAR CANCER THERAPEUTICS (2016)

Article Plant Sciences

Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines

Christopher R. Bodle, Duncan I. Mackie, Michael P. Hayes, Josephine H. Schamp, Michael R. Miller, Michael D. Henry, Jonathan A. Doom, Jon C. D. Houtman, Michael A. James, David L. Roman

JOURNAL OF NATURAL PRODUCTS (2017)

Article Oncology

Modulation of Gene Expression and Cell-Cycle Signaling Pathways by the EGFR Inhibitor Gefitinib (Iressa) in Rat Urinary Bladder Cancer

Yan Lu, Pengyuan Liu, Francoise Van den Bergh, Victoria Zellmer, Michael James, Weidong Wen, Clinton J. Grubbs, Ronald A. Lubet, Ming You

CANCER PREVENTION RESEARCH (2012)

Article Oncology

CRR9/CLPTM1L Regulates Cell Survival Signaling and Is Required for Ras Transformation and Lung Tumorigenesis

Michael A. James, Haris G. Vikis, Everett Tate, Amy L. Rymaszewski, Ming You

CANCER RESEARCH (2014)

Article Oncology

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing

Pengyuan Liu, Carl Morrison, Liang Wang, Donghai Xiong, Peter Vedell, Peng Cui, Xing Hua, Feng Ding, Yan Lu, Michael James, John D. Ebben, Haiming Xu, Alex A. Adjei, Karen Head, JaimeW. Andrae, Michael R. Tschannen, Howard Jacob, Jing Pan, Qi Zhang, Francoise Van den Bergh, Haijie Xiao, Ken C. Lo, Jigar Patel, Todd Richmond, Mary-Anne Watt, Thomas Albert, Rebecca Selzer, Marshall Anderson, Jiang Wang, Yian Wang, Sandra Starnes, Ping Yang, Ming You

CARCINOGENESIS (2012)

Article Biochemistry & Molecular Biology

Dietary Administration of Berberine or Phellodendron amurense Extract Inhibits Cell Cycle Progression and Lung Tumorigenesis

Michael A. James, Huijing Fu, Yan Liu, Da-Ren Chen, Ming You

MOLECULAR CARCINOGENESIS (2011)

Article Genetics & Heredity

Principles for the post-GWAS functional characterization of cancer risk loci

Matthew L. Freedman, Alvaro N. A. Monteiro, Simon A. Gayther, Gerhard A. Coetzee, Angela Risch, Christoph Plass, Graham Casey, Mariella De Biasi, Chris Carlson, David Duggan, Michael James, Pengyuan Liu, Jay W. Tichelaar, Haris G. Vikis, Ming You, Ian G. Mills

NATURE GENETICS (2011)

Article Multidisciplinary Sciences

Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus

Michael A. James, Weidong Wen, Yian Wang, Lauren A. Byers, John V. Heymach, Kevin R. Coombes, Luc Girard, John Minna, Ming You

PLOS ONE (2012)

Article Biochemistry & Molecular Biology

Single-nucleotide polymorphism rs13426236 contributes to an increased prostate cancer risk via regulating MLPH splicing variant 4

Fankai Xiao, Peng Zhang, Yuan Wang, Yijun Tian, Michael James, Chiang-Ching Huang, Lidong Wang, Liang Wang

MOLECULAR CARCINOGENESIS (2020)

Article Oncology

Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance

Deepak Parashar, Anjali Geethadevi, Donna McAllister, Johnathan Ebben, Francis C. Peterson, Davin R. Jensen, Erin Bishop, Sunila Pradeep, Brian F. Volkman, Michael B. Dwinell, Pradeep Chaluvally-Raghavan, Michael A. James

Summary: Recurrence of therapy-resistant tumors remains a major challenge in the field of solid tumor oncology, particularly in ovarian and pancreatic cancer. High expression of CLPTM1L in ovarian tumor cells is associated with poor prognosis, and inhibiting CLPTM1L can re-sensitize resistant ovarian cancer cells to platinum-based therapy. Additionally, CLPTM1L can confer intercellular resistance to chemotherapeutic killing in an ectodomain-dependent manner, which can be blocked by anti-CLPTM1L biologics.

NPJ PRECISION ONCOLOGY (2021)

暂无数据